Tag Archives: Type 2 Diabetes

Insights: The Lucrative Business Of Diabetes (2022)

In our modern consumer society, Type 2 diabetes has become a widespread disease. Companies are developing drugs that are increasingly expensive, but not necessarily more effective. Health authorities are powerless. Diabetes is spreading rapidly, all over the world.

The disease destroys lives and puts a strain on public budgets. The UN is calling on governments to take action. Diabetes is proof that modern societies are incapable of adequately treating chronic disease. It affects around 430 million people worldwide, with two main metabolic disorders falling under the name diabetes.

Type 1 is an autoimmune disease that must be treated with lifelong doses of insulin, while type 2 can develop when a person’s diet is too high in fat and sugar and they do not engage in enough physical activity. With turnover of $46 billion, diabetes is a massive and extremely lucrative market. Constantly promised miracle cures have not led to satisfactory treatment, with patients either taking too many drugs or no longer being able to afford them.

It’s a desperate situation, and the only ones benefiting seem to be pharmaceutical companies. A medical focus on blood glucose levels has led to an overreliance on medication, sometimes without due concern for dangerous side effects. Patients become trapped in a cycle of treatment, which in many cases still does not halt the disease’s progression. This can lead to amputations, blindness and heart attacks.

And yet there are alternatives that could flatten the curve of the type 2 diabetes epidemic, while reducing health care spending. Improved diet can be a preventative measure, and a strict adherence to diet can also bring about remission in the case of Type 2 diabetes. But these solutions require effort, as well as a complete rethinking of chronic disease management. Filmed on three continents, this documentary features industry whistleblowers, patients, researchers and medical professionals. It also confronts pharmaceutical companies about their responsibility for the situation.

Studies: Covid Increases Type 2 Diabetes Risk By 40%

The true disability cost of the COVID-19 pandemic is still unknown, but more and more studies are adding to the list of potential fallout from even mild COVID 19 infection. 

In this episode of Coronapod we discuss a massive association study which links COVID-19 cases with an increase in the risk of developing type 2 diabetes. We delve into the numbers to ask how big the risk might be? Whether any casual relationship can be drawn from this association? And what might be in store from future research into COVID and chronic disease?

News: Diabetes risk rises after COVID, massive study finds

Medicine: Is Metformin A Wonder Drug? (Harvard)

DIABETES: THE ROLE OF INSULIN AND ISLETS (VIDEO)

Type 1 and type 2 diabetes are characterized by increased blood glucose levels. They affect almost half a billion people around the globe, and this number is projected to rise as we reach the middle of the century. In most individuals, blood glucose levels are kept within a healthy range by a hormone called insulin, which is secreted by the pancreas, but this fine-tuned regulation can go wrong in type 1 and type 2 diabetes. In this animation, we lay out our current understanding of these diseases and explore active areas of research that aim to restore the body’s blood glucose control.

MEDICINE: ‘DIABETES’ – RISKS & DIAGNOSIS (BMJ PODCAST)

In this episode of the JIM Podcast, Editor-in-Chief Richard McCallum speaks with David Cistola of Texas Tech University Health Sciences Center El Paso about American Diabetes Month.

HEALTH: ‘DIABETES AND CHRONIC KIDNEY DISEASE’ – NEW GUIDELINES (OCT 2020)

Comprehensive care in patients with diabetes and CKD

Management of CKD in diabetes can be challenging and complex, and a multidisciplinary team should be involved (doctors, nurses, dietitians, educators, etc). Patient participation is important for self-management and to participate in shared decision-making regarding the management plan. (Practice point).

We recommend that treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) be initiated in patients with diabetes, hypertension, and albuminuria, and that these medications be titrated to the highest approved dose that is tolerated (1B).

Lifestyle interventions in patients with diabetes and CKD

We suggest maintaining a protein intake of 0.8 g protein/kg)/d for those with diabetes and CKD not treated with dialysis (2C).

On the amount of proteins recommended in these guidelines, they suggest (‘recommend’ becomes a ‘suggest’ at this level of evidence) a very precise  intake of 0.8g/kg/d in patients with diabetes and CKD. Lower dietary protein intake has been hypothesized but never proven to reduce glomerular hyperfiltration and slow progression of CKD, however in patients with diabetes, limiting protein intake below 0.8g/kg/d can be translated into a decreased caloric content, significant weight loss and quality of life. Malnutrition from protein and calorie deficit is possible.

Physical activity

We recommend that patients with diabetes and CKD be advised to undertake moderate-intensity physical activity for a cumulative duration of at least 150 minutes per week, or to a level compatible with their cardiovascular and physical tolerance (1D).

Read full guidelines

STUDIES: “INSOMNIA / SHORT SLEEP DURATION” IS A TYPE 2 DIABETES “RISK FACTOR”

Diabetologia  (Sept 8, 2020) – Insomnia with objective short sleep duration has been associated with an increased risk of type 2 diabetes in observational studies [2728]. The present MR study found strong and suggestive evidence of a causal association of insomnia and short sleep duration, respectively, with increased risk of type 2 diabetes.

Conclusions/interpretation

The present study verified several previously reported risk factors and identified novel potential risk factors for type 2 diabetes. Prevention strategies for type 2 diabetes should be considered from multiple perspectives on obesity, mental health, sleep quality, education level, birthweight and smoking.

Read full study

COMMENTARY

This was a laborious and apparently objective study.

The discovery of insomnia as a unique risk factor is no surprise, and reinforces the restorative IMPORTANCE of SLEEP.

I was surprised to see docosohexanoic and Eicosapentanoic acids in the risk column and LDL in the good column. However they were studying type 2 diabetes, and not vascular health. I will continue to take my fish oil, and enjoy my HDL, which is in the good column.

—Dr. C.

VIDEOS: STARTING INSULIN EARLY FOR TYPE 2 DIABETES

JAMA NETWORK (AUG 5, 2020): 2020 American Diabetes Association (ADA) guidelines recommend that after a trial of metformin, doctors add additional drugs based on the presence of cardiovascular and kidney-related comorbidities, risk of weight gain and hypoglycemia, and cost. In this video, Irl B. Hirsch, MD, of the University of Washington in Seattle, explains the rationale for starting insulin next for patients with persistent HbA1c elevation above 9-9.5% despite lifestyle changes and metformin.

Click https://ja.ma/2DhR4DV for complete details.